Checkpoint blockade involves use of ICIs targeting immune checkpoint proteins, including PD-1 and CTLA-4 inhibitory receptors expressed by T cells, as well as PD-1 ligands 1 and 2 (PD-L1, PD-L2) expressed by stromal and tumor cells. The gene discussed is CD274; the disease is neoplasm.